Live Analyst Rating Changes 46577 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Lu Li
BofA

Lu Li

Bank of America Securities
Wall Street Analyst
★★★☆☆
#1124
on 13Foresight · ranked by our own returns
86%
Success Rate
+8.3%
Average Return
19 of 22 calls profitable · +36.7% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 86% of Lu Li's ratings turned a profit when each position was held for 1 year — averaging +8.3% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

11 Buy 15 Hold 2 Sell
Lu's Stock Coverage 16 ratings · 2026-10-24
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
DHR
Danaher
 Oct 21, 2026 BUY Strong Buy
-3.1% avg upside
47 analysts
$270.00
18.18% Upside
 -1.4% ·
MYGN
Myriad Genetics
 Oct 20, 2026 SELL Sell
+187.9% avg upside
24 analysts
$3.20
44.69% Downside
 -4.0% ·
LH
Labcorp Holdings
 Oct 15, 2026 BUY Strong Buy
-17.5% avg upside
38 analysts
$360.00
8.99% Upside
 +1.2% ·
QGEN
Qiagen
 Oct 09, 2026 BUY Buy
-12.5% avg upside
25 analysts
$50.00
0.78% Downside
 +10.2% ·
RVTY
Revvity
 Oct 09, 2026 HOLD Buy
-20.2% avg upside
25 analysts
$165.00
4.30% Upside
 +1.6% ·
GH
Guardant Health
 Oct 09, 2026 BUY Strong Buy
+2.5% avg upside
33 analysts
$200.00
17.16% Upside
 +1.0% ·
AVTR
Avantor
 Oct 09, 2026 HOLD Buy
-6.1% avg upside
27 analysts
$17.00
1.14% Downside
 +4.8% ·
TEM
Tempus AI, Inc. Class A
 Oct 09, 2026 HOLD Buy
+7.4% avg upside
25 analysts
$75.00
10.83% Upside
 -4.7% ·
CAI
Caris Life Sciences, Inc.
 Oct 09, 2026 BUY Strong Buy
-3.3% avg upside
21 analysts
$35.00
10.70% Upside
 +7.7% ·
ICLR
Icon
 Oct 09, 2026 HOLD Strong Buy
+0.9% avg upside
28 analysts
 — +13.0% ·
ILMN
Illumina
 Oct 09, 2026 SELL Buy
-23.1% avg upside
32 analysts
$168.00
37.56% Downside
 +3.1% ·
NEO
NeoGenomics
 Oct 07, 2026 HOLD Strong Buy
+15.5% avg upside
19 analysts
 — +2.6% ·
QDEL
QuidelOrtho
 May 07, 2026 HOLD Buy
+189.2% avg upside
13 analysts
$12.00
10.75% Downside
 +27.5% ·
WAT
Waters
 May 06, 2026 HOLD Strong Buy
-10.7% avg upside
31 analysts
$375.00
17.09% Downside
 +15.8% ·
VCYT
Veracyte
 May 06, 2026 BUY Strong Buy
+9.6% avg upside
19 analysts
$52.00
9.37% Upside
 +6.5% ·
FLGT
Fulgent Genetics
 Mar 02, 2026 BUY Buy
+120.7% avg upside
7 analysts
$22.00
9.62% Upside
 +41.0% ·
🔒 11 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Lu Li — Frequently Asked Questions
How accurate are Lu Li's stock ratings?
Based on the calls 13Foresight could measure, about 82% of Lu's ratings were profitable over a one-year hold, with an average return of +7.9% per rating, or +38.3% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Lu ranked on 13Foresight?
Lu Li is currently ranked #1124 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Lu cover?
Lu most recently has ratings on DHR, MYGN, LH, QGEN, RVTY, GH, AVTR, TEM, CAI, ICLR, ILMN, NEO and 4 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.